bioAffinity Technologies， Inc. focuses on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung， and targeted cancer therapeutics. The Company has developed a proprietary platform for in vitro diagnostics of which the first is a noninvasive test for early detection of lung cancer. The Company’s diagnostic tests are based on platform technologies that may be applicable to detecting other lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma， and diagnosing other types of cancer such as prostate and bladder cancers.

bioAffinity Technologies, Inc.在纳斯达克交易所上市，股票简称为：bioAffinity Technologies Inc，股票代码为：BIAF.O。